Oncolys BioPharma Inc. [4588.T]
TOKYO, May 18 (Pulse News Wire) – Oncolys BioPharma Inc. (4588.T) announced today that it has received approval for a divisional patent application related to the endoscopic administration method of its tumor-dissolving virus OBP-301.
This follows the initial patent granted in 2025, which covered the administration methods of tumor-dissolving adenoviruses. The newly approved patent expands the scope of protection beyond the limitations set in the previous patent, removing restrictions on the duration of administration.
As a result, the applicability of OBP-301 and potential uses for another product, OBP-702, have broadened significantly. The expanded patent remains valid until May 2040.
Regarding the impact on the company's financial performance, Oncolys BioPharma stated that the effects on its fiscal year ending December 2026 would be minor.
🟢 Confidence: High AI-translated content.